Published in Women's Health Weekly, May 9th, 2002
This product was a subject of a patent challenge initiated in September 2000. The company expects to be the first to market generic Mircette and is launching the product immediately. The company plans to market the product as a branded generic using the Kariva trademark.
Mircette is a 28-tablet regimen that represents a combination of desogestrel/ethinyl estradiol and ethinyl estradiol.
"The launch of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.